Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design

Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design

Background: The impact of COVID-19-related healthcare changes on access to buprenorphine (BUP) nationwide in the US is unknown. Methods: We conducted an interrupted time series with the IQVIA LRx database. The study timeline included BUP prescriptions from 52 weeks before (2/23/19–2/21/20) to 52 wee...

Full description

Bibliographic Details
Main Authors: Payel Jhoom Roy, Katherine Callaway Kim, Katie Suda, Jing Luo, Xiaoming Wang, Donna Olejniczak, Jane M Liebschutz
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Drug and Alcohol Dependence Reports
Subjects:
Buprenorphine
COVID-19
Buprenorphine-naloxone
Access
Pandemic
Online Access:http://www.sciencedirect.com/science/article/pii/S2772724623000057

Similar Items

Similar Items